Provided by Tiger Trade Technology Pte. Ltd.

CSPC PHARMA

9.930
-0.140-1.39%
Volume:45.90M
Turnover:453.22M
Market Cap:114.41B
PE:24.97
High:10.040
Open:9.955
Low:9.670
Close:10.070
52wk High:10.720
52wk Low:6.387
Shares:11.52B
HK Float Shares:11.52B
Volume Ratio:0.55
T/O Rate:0.40%
Dividend:0.29
Dividend Rate:2.92%
EPS(LYR):0.398
ROE:20.90%
ROA:10.70%
PB:2.60
PE(LYR):24.97
PS:3.12

Loading ...

Hong Kong Stock Exchange News Highlights: Beone Medicines Sees 111% Surge in Adjusted Net Profit for First Half of the Year

Stock News
·
Aug 06

CSPC Pharma Secures US$10.00 million Milestone Payment from AstraZeneca under Small-Molecule R&D Pact

Bulletin Express
·
Aug 05

CSPC Pharmaceutical Receives USD 10 Million AstraZeneca Milestone Payment Under Research Pact

Reuters
·
Aug 05

CSPC Pharma and AstraZeneca to Establish 51/49 Joint Venture for Next-Generation Biologics Facility in Shijiazhuang

Bulletin Express
·
Aug 05

CSPC Pharmaceutical and AstraZeneca Enter JV for Biologics Facility in China

Reuters
·
Aug 05

CSPC Pharmaceutical Group Stock Falls 1.3% in Hong Kong, Underperforms Competitors

Dow Jones
·
Aug 05

CSPC Pharma, AstraZeneca Form Biologics Manufacturing JV in China with 51%-49% Split

Reuters
·
Aug 05

CSPC Pharmaceutical - Co to Hold 51% and AstraZeneca 49% in Joint Venture

THOMSON REUTERS
·
Aug 05

CSPC Pharmaceutical - Joint Venture to Manufacture Biologics Drug Substances for Global Markets

THOMSON REUTERS
·
Aug 05

CSPC Pharma Unit, Alphamab Oncology's Breast Cancer Drug Application Granted Priority Review in China

MT Newswires Live
·
Aug 04

CSPC Says NMPA Accepts NDA for Anbenitamab, Albumin-Bound Docetaxel Neoadjuvant Breast Cancer Combo Under Priority Review

Reuters
·
Aug 04

Alphamab Oncology Says NMPA Accepts NDA for Anbenitamab (kn026)

Reuters
·
Aug 04

CSPC Pharma Begins Phase Ib/II Trial of Colorectal Cancer Drug Candidate

MT Newswires Live
·
Aug 03

CSPC Pharmaceutical - Initiates Phase Ib/Ii Trial of Sys 6090 Injection for Colorectal Cancer in China

THOMSON REUTERS
·
Aug 03

CSPC Pharmaceutical Group Stock Falls 1.3% in Hong Kong

Dow Jones
·
Aug 03

Movement Alert|CSPC PHARMA Falls 3.03% in Regular Trading, Trading at HK$8.31

Market Focus
·
Aug 03

CSPC Pharma Wins China Trial Approval for RSV Vaccine

MT Newswires Live
·
Aug 03

CSPC Pharmaceutical Group's SYS6041 Combination Therapy Phase II Trial for Recurrent Ovarian Cancer Has Officially Launched at the First Center in China

Stock News
·
Jul 31

CSPC Pharma Secures NMPA Clearance to Begin Clinical Trials for Second Recombinant RSV Vaccine

Bulletin Express
·
Jul 31

CSPC Pharma Says China Clears Clinical Trial for RSV Vaccine Candidate SYS 6057

Reuters
·
Jul 31